Highlights

06-10 XtalPi Signs Drug Development Agreement with Potential Value of Over $400 Million MT
03-25 XtalPi Holdings posts FY profit attributable RMB123.7 million RE
03-25 XtalPi Turns to 2025 Profit MT
03-03 XtalPi Forecasts Full-Year Profit for First Time in 2025 MT
03-03 XtalPi sees increase in group's revenue to not less than RMB780 million for FY RE
11-05 XtalPi Unit Enters Collab Contract for Bispecific Antibody Discovery, Development MT
27/08/25 XtalPi Turns to H1 Profit Amid 404% Revenue Boost MT
12/08/25 XtalPi to Swing to Profit in H1 MT
12/08/25 XtalPi sees HY revenue of at least RMB500 mln RE
06/08/25 XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8% MT
05/08/25 XtalPi says in late June, unit and Dovetree enter definitive agreement RE
23/06/25 XtalPi Signs AI Drug Discovery Term Sheet With DoveTree; Shares Slide 4% MT
12/06/25 XtalPi Completes Acquisition of UK's LCC Technologies; Shares Up 5% MT
19/02/25 XtalPi Holdings Unit Advances AI, Automation Project in Greater Bay Area MT
29/01/25 XtalPi Holdings Raises HK$1.13 Billion via Share Placement MT
20/01/25 XtalPi Holdings Seeks to Raise HK$1.13 Billion via Share Placement MT
05/12/24 XtalPi Holdings Changes Name from QuantumPharm MT
08/11/24 QuantumPharm Signs MOU with Indonesia Firm for AI, Automation Collaboration in Southeast Asia MT
18/10/24 QuantumPharm to Change Name MT
29/08/24 QuantumPharm's H1 Loss Widens Despite Higher Revenue; Shares Surge 17% MT
13/06/24 QuantumPharm Shares Increase Over 2% in Hong Kong Debut MT
13/06/24 QuantumPharm Raises HK$896 Million in Hong Kong IPO MT
04/06/24 QuantumPharm Launches Up to HK$1.1 Billion Hong Kong IPO MT
11/02/22 Cecep Costin to Be Delisted from Hong Kong Bourse on Feb. 14 MT
10/02/22 Cecep Costin New Materials Loses Appeal Against Delisting Order MT
No results match your criteria